Results 111 to 120 of about 14,363 (238)

Development of a physiologically‐based pharmacokinetic model for Ritonavir characterizing exposure and drug interaction potential at both acute and steady‐state conditions

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 523-539, March 2025.
Abstract Ritonavir (RTV) is a potent CYP3A inhibitor that is widely used as a pharmacokinetic (PK) enhancer to increase exposure to select protease inhibitors. However, as a strong and complex perpetrator of CYP3A interactions, RTV can also enhance the exposure of other co‐administered CYP3A substrates, potentially causing toxicity.
Lien Thi Ngo, Woojin Jung, Tham Thi Bui, Hwi‐yeol Yun, Jung‐woo Chae, Jeremiah D. Momper   +5 more
wiley   +1 more source

Prediction of Pharmacokinetic Drug–Drug Interactions Involving Anlotinib as a Victim by Using Physiologically Based Pharmacokinetic Modeling

Drug Design, Development and Therapy
Fengjiao Bu,1,2,* Yong-Soon Cho,3,4,* Qingfeng He,1 Xiaowen Wang,1 Saurav Howlader,3,4 Dong-Hyun Kim,3,4 Mingshe Zhu,5 Jae Gook Shin,3,4 Xiaoqiang Xiang1,6 1Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan ...
Bu F, Cho YS, He Q, Wang X, Howlader S, Kim DH, Zhu M, Shin JG, Xiang X   +8 more
doaj  

Disease–Drug–Drug Interaction of Imatinib in COVID‐19 ARDS: A Pooled Population Pharmacokinetic Analysis

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 583-595, March 2025.
ABSTRACT Prior pharmacokinetic (PK) analysis revealed that increased alpha‐1‐acid glycoprotein (AAG) levels are associated with decreased imatinib unbound fraction in coronavirus disease 2019 (COVID‐19) patients. This study aimed to investigate the PK of total and unbound concentrations of imatinib and the metabolite N‐desmethyl imatinib in ...
Medhat M. Said, Job R. Schippers, Leila Atmowihardjo, Yingxue Li, Mick S. van der Plas, Harm J. Bogaard, Lieuwe D. J. Bos, Ron A. A. Mathôt, Jurjan Aman, Eleonora L. Swart, Imke H. Bartelink   +10 more
wiley   +1 more source

Use of Physiologically Based Pharmacokinetic (PBPK) Models in Marine Mammal Toxicology [PDF]

, 2012
peer reviewedPhysiologically based pharmacokinetic (PBPK) models are mathematical models that are largely based upon the physiological characteristics of the species and the biochemical properties of the chemical of interest. They quantitatively describe
Blust, Ronny, Covaci, Adrian, Das, Krishna, Weijs, Liesbeth, Yang, Raymond S.H.   +4 more
core  

Transforming Treatment: The Impact of Bariatric Surgery on Oral Drug Absorption

Obesity Reviews, EarlyView.
ABSTRACT Obesity represents a significant threat to global public health, with an estimated 16% of adults worldwide (2022) being classified as people with obesity, with a body mass index of 30 or more. Bariatric surgery is regarded as the most effective treatment option for people with obesity, with the three main types of bariatric surgery being ...
Danielle Wigg, Andrea Edginton, Matthew D. Jones, Nikoletta Fotaki   +3 more
wiley   +1 more source

An IQ Consortium Perspective on the FDA Guidance for Assessment of Pharmacokinetics in Participants With Impaired Renal Function

Clinical Pharmacology &Therapeutics, Volume 119, Issue 4, Page 838-845, April 2026.
The FDA published guidance on assessing pharmacokinetics (PK) in participants with impaired renal function in 2024. The IQ CPLG Organ Impairment Working Group summarized the industry’s perspective on this guidance by highlighting a few key updates in the 2024 guidance, including: (1) the recommendation of using estimated glomerular filtration rate ...
Yan Jin, Ashish Sharma, Mariam A. Ahmed, Sravanthi Cheeti, Ying Ou, Damayanthi Devineni, Yizhe Chen, Jitendra S. Kanodia, Yasmeen Abouelhassan, Nadia Noormohamed, Jin Zhou, Patrick Marroum, Vaishali Sahasrabudhe, Islam R. Younis   +13 more
wiley   +1 more source

Evaluation of Luteolin Nanosuspensions on Pharmacokinetics of Atorvastatin: Drug-Drug Interactions Using Rat Models

International Journal of Nanomedicine
You Liang,* Bo Sun,* Min Yang, Xiaona Meng, Meng Wang, Lijuan Yang, Bandar AI-Hamyari, Yuqian Zhang, Yutong Shen, Shengnan Meng Department of Pharmaceutics, School of Pharmacy, China Medical University, Shenyang, 110122, People’s Republic of ...
Liang Y, Sun B, Yang M, Meng X, Wang M, Yang L, AI-Hamyari B, Zhang Y, Shen Y, Meng S   +9 more
doaj  

Predicting Drug Transfer Into Human Milk With the Simcyp Simulator: A Contribution From the ConcePTION Project

CPT: Pharmacometrics & Systems Pharmacology
Physiologically‐based pharmacokinetic (PBPK) modeling can support decision‐making on maternal medication use during breastfeeding. This study aimed to enhance lactation PBPK models in two ways.
Julia Macente, Nina Nauwelaerts, Justine Marine Badée, Rodolfo Hernandes Bonan, Miao‐Chan Huang, Martje Van Neste, Anne Smits, Karel Allegaert, Hedvig Nordeng, Markus Hovd, Frederico Severino Martins, Pieter Annaert   +11 more
doaj   +1 more source

Quantitative Systems Toxicology Modeling with DILIsym to Support Phase 3 Dose Selection for Fezolinetant

Clinical Pharmacology &Therapeutics, Volume 119, Issue 4, Page 1016-1024, April 2026.
Fezolinetant is a first‐in‐class, selective, non‐hormonal, neurokinin 3 receptor antagonist that is approved for the treatment of moderate to severe vasomotor symptoms due to menopause. In a phase 2b clinical study (n = 352), nine study participants experienced elevations in serum transaminases exceeding three times the upper limit of normal.
Jace C. Nielsen, Jeffrey L. Woodhead, Brett A. Howell, Lisl K. M. Shoda, Dolly A. Parasrampuria, Jiayin Huang, Megumi Iwai, Faith D. Ottery, Xuegong Wang, Marci English, Kentaro Miyazaki, Paul B. Watkins   +11 more
wiley   +1 more source

EuroMix PBPK model for combined exposures

, 2019
In this paper documents the structure and default parameter values of the EuroMix PBPK model implemented in the MCRA platform for rats and humans. A version allowing apportionment of results by exposure routes is also described. Finally, the extensions needed to describe pharmacokinetic interactions between pairs or triplets of substance are discussed.
Bois, F.Y., Tebby, C., Brochot, C.
openaire   +1 more source